Rouan Sarah Kathryn's Form 4/A amendment
AmendedViking Therapeutics, Inc. (VKTX) · filed Apr 8, 2025
- Accession no.
- 0000950170-25-052255
- Filed
- Apr 8, 2025
- Trade date
- Mar 31, 2025
- Filing delay
- 8 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Apr 2, 2025
This filing lists 1 non-derivative transaction. Open-market purchases total $29.9K. It was filed 8 days after the trade.
This amendment replaces 0000950170-25-049717 (filed Apr 2, 2025).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rouan Sarah KathrynCIK 0001761366 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 31, 2025 | Common Stock, par value $0.00001 per share | PPurchaseAcquired | +1,240 | $24.15 | +$29,946 | 1,240 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Reporting Person's purchase of shares of the Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 1,240 shares, with the Reporting Person's sale of shares of the Issuer's common stock at a price of $80.89 per share on October 25, 2024. The Reporting Person has, on a voluntary basis, made arrangements with the Issuer to pay $70,316.25 to the Issuer, representing the full amount of the profit realized in connection with the short-swing transaction, less transactions costs.
Remarks
This Form 4 is being amended solely to add new footnote 1 regarding the Reporting Person's agreement to pay the profit realized to the Issuer.